Alloreactivity in Renal Transplant Recipients with and without Chronic Allograft Nephropathy
- 1 July 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 15 (7) , 1952-1960
- https://doi.org/10.1097/01.asn.0000129980.83334.79
Abstract
The pathogenesis of chronic allograft nephropathy (CAN) involves both immunologic (antigen-dependent) and nonimmunologic (antigen-independent) mechanisms. In order to provide further insight into the immunologic basis of this disease, a cross-sectional analysis of cellular and humoral immunity in human renal allograft recipients with or without deteriorating renal function and biopsy proven CAN was performed. Interferon-γ enzyme-linked immunosorbent spot assays were used to assess cellular immunity to donor, or fully mismatched third-party stimulator cells (direct pathway), and to synthetic peptides derived from donor HLA molecules (indirect pathway). Anti-HLA antibodies were evaluated by flow cytometry using HLA-coated beads. Both the mean frequencies of donor-reactive peripheral blood lymphocytes and the number of individuals who responded to donor antigens per group were statistically higher in CAN patients versus control subjects (P < 0.02). Calculated ratios of donor/third-party enzyme-linked immunosorbent spot responses showed mean values of 2.61 ± 3.0 in the CAN group, with ratios of 0.50 to 0.72 ± 0.42 in control subjects (P < 0.001), confirming that direct, donor-specific cellular immunity predominated in patients with CAN. Fifty percent of CAN patients studied exhibited donor peptide reactivity compared with only 28.6% in control subjects. Finally, 33% of patients in the CAN group developed new posttransplantation anti-HLA antibodies compared with only 4% in the control group (P < 0.05). Overall, the results suggest that persistent cell-mediated and humoral alloimmunity contribute to the development of CAN and further demonstrate that anti-donor immunity in patients with CAN is heterogeneous. Immune monitoring to predict long-term outcome should include multiple measures of cellular and humoral immunity.Keywords
This publication has 39 references indexed in Scilit:
- Risk of Renal Allograft Loss from Recurrent GlomerulonephritisNew England Journal of Medicine, 2002
- Call for Revolution: A New Approach to Describing Allograft DeteriorationAmerican Journal of Transplantation, 2002
- Indirect allorecognition promotes the development of cardiac allograft vasculopathyTransplantation Proceedings, 2001
- Improved Graft Survival after Renal Transplantation in the United States, 1988 to 1996New England Journal of Medicine, 2000
- Chronic allograft nephropathy: An updateKidney International, 1999
- CELLULAR AND HUMORAL MECHANISMS OF VASCULARIZED ALLOGRAFT REJECTION INDUCED BY INDIRECT RECOGNITION OF DONOR MHC ALLOPEPTIDES1Transplantation, 1999
- ALLOANTIBODY- AND T CELL-MEDIATED IMMUNITY IN THE PATHOGENESIS OF TRANSPLANT ARTERIOSCLEROSISTransplantation, 1997
- Cardiac Allograft Vasculopathy Is Abrogated by Anti-CD8 Monoclonal Antibody TherapyThe Annals of Thoracic Surgery, 1997
- Cardiac allograft vasculopathy in partially inbred miniature swine. I. Time course, pathology, and dependence on immune mechanismsThe Journal of Thoracic and Cardiovascular Surgery, 1996
- Chronic renal allograft rejection: Immunologic and nonimmunologic risk factorsKidney International, 1996